Compare Heron Therapeutics Inc (HRTX) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Macy's Inc — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Macy's Inc trades at $22.88 (market cap $5.95B). The key difference: Macy's Inc is far larger — about 80.4× Heron Therapeutics Inc's market cap, and Macy's Inc pays a 3.36% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Macy's Inc for 58 Days on average.
| HRTX | M | |
|---|---|---|
Market Cap | $74.04M | $5.95B |
Volume | 3,668,095 | 11,329,747 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $26.21 |
52-Week Low | $0.27 | $16.51 |
Typical Hold Time | 35 Days | 58 Days |
Enterprise Value | $180.78M | $9.75B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Macy's stock trades at $22.79, up 1.47% with a bullish technical signal and strong valuation metrics including a P/E of 8.35 and P/S of 0.27. The company has beaten earnings estimates for three consecutive quarters and maintains a 3.5% dividend yield. Recent 'Bold New Chapter' strategy initiatives are showing traction with improved sales and operational metrics.
The stock offers attractive value with upside to the $24.25 consensus target, though Q3 earnings risk and retail sector headwinds remain concerns. Positive cash flow generation and debt reduction support the dividend, while digital transformation efforts provide growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
